Azenta, Inc.
AZTANasdaq
$26.29
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↓ -18.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.2B
Enterprise Value
$830.5M
P/E
—
P/S
2.0
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
2.5%
Dividend Yield
—
Revenue (TTM)
$596.5M
Net Income (TTM)
-$173.3M
Free Cash Flow (TTM)
$30.0M
Gross Margin
44.3%
Operating Margin
-29.0%
Net Margin
-29.1%
ROE
-11.2%
ROIC
-11.6%
Debt / Equity
—
Net Cash
$380.5M
Return 1Y
-18.1%
Company profile
Azenta, Inc. provides manufacturing automation solutions for the semiconductor industry. The company operates in two segments, Life Sciences Products and Life Sciences Services. The Life Sciences products segment offers automated ultra-cold storage systems and consumables, including racks, tubes, caps, plates, and foils.
- CEO
- Stephen S. Schwartz
- Sector
- Manufacturing
- Industry
- Machinery
- Employees
- 3,100
- Headquarters
- Massachusetts
- Website
- azenta.com
Management & directors
- Starr EphraimSVP, Gen Counsel & Secretary
- Martin William E. IiiPresident Multiomics
- Lin Lawrence Y.EVP, CFO and Treasurer
- Marotta JohnPresident and CEO
- Pirogova OlgaSVP and CHRO
- Zhou GingerSVP and GM, Multiomics
Roles derived from SEC Form 4 filings.
Earnings
AZTA Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$144.8M↑ +1.0%
Diluted EPS-$3.49↑ +235.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $388.5M | $513.7M | $555.5M | $551.5M | $573.4M | $593.8M |
| Gross profit | $172.1M | $243.8M | $255.6M | $239.2M | $254.6M | $270.3M |
| Operating income | -$36.6M | -$31.1M | -$24.7M | -$61.2M | -$51.3M | -$26.8M |
| Net income | $64.9M | $110.7M | $2.1B | -$14.6M | -$164.9M | -$55.8M |
| Diluted EPS | $0.88 | $1.49 | $28.48 | -$0.22 | -$3.10 | -$1.22 |
| Operating cash flow | $37.9M | $149.9M | -$466.0M | $5.8M | $49.7M | $72.2M |
| Free cash flow | -$2.1M | $97.1M | -$539.5M | -$33.6M | $12.4M | $38.3M |
| Gross margin | 44.3% | 47.5% | 46.0% | 43.4% | 44.4% | 45.5% |
| Operating margin | -9.4% | -6.1% | -4.5% | -11.1% | -8.9% | -4.5% |
| Net margin | 16.7% | 21.6% | 384.0% | -2.7% | -28.8% | -9.4% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $144.3M | $150.6M | $147.4M | $143.3M | $143.9M | $159.2M | $148.6M | $144.8M |
| Gross profit | $64.6M | $68.5M | $68.8M | $62.8M | $66.4M | $72.3M | $63.7M | $62.0M |
| Operating income | -$7.1M | -$4.6M | -$8.7M | -$18.2M | -$1.9M | $1.9M | -$7.2M | -$165.8M |
| Net income | -$6.6M | -$6.6M | -$11.0M | -$47.7M | -$48.0M | $50.9M | -$15.4M | -$160.8M |
| Diluted EPS | -$0.12 | -$0.14 | -$0.25 | -$1.04 | -$1.05 | $1.11 | -$0.34 | -$3.49 |
| Operating cash flow | $9.8M | $17.7M | $29.8M | $14.4M | $25.8M | $2.2M | $20.8M | $13.5M |
| Free cash flow | $1.3M | $8.3M | $22.0M | $7.0M | $15.0M | -$5.7M | $14.7M | $6.1M |
| Gross margin | 44.8% | 45.5% | 46.7% | 43.8% | 46.2% | 45.4% | 42.9% | 42.8% |
| Operating margin | -4.9% | -3.1% | -5.9% | -12.7% | -1.3% | 1.2% | -4.9% | -114.5% |
| Net margin | -4.5% | -4.4% | -7.5% | -33.3% | -33.4% | 32.0% | -10.4% | -111.1% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Cornog William L | Buy | 10,000 | $16.38 | $163,800.00 | filing |
| 2026-05-15 | Starr Ephraim· SVP, Gen Counsel & Secretary | Tax withholding | 3,621 | $16.02 | $58,008.42 | filing |
| 2026-04-28 | MARTIN WILLIAM E. III· President Multiomics | Award | 17,790 | $24.24 | $431,229.60 | filing |
| 2026-02-06 | Nova Tina Susan | Award | 5,663 | $27.85 | $157,714.55 | filing |
| 2026-02-05 | Casal Frank | Award | 7,243 | $27.85 | $201,717.55 | filing |
| 2026-02-05 | Doshi Dipal | Award | 5,663 | $27.85 | $157,714.55 | filing |
| 2026-02-05 | McLaughlin Erica | Award | 5,663 | $27.85 | $157,714.55 | filing |
| 2026-02-05 | Koffey Quentin | Award | 5,663 | $0.00 | $0.00 | filing |
| 2025-11-24 | Zhou Ginger· SVP and GM, Multiomics | Award | 13,042 | $0.00 | $0.00 | filing |
| 2025-11-24 | Marotta John· President and CEO | Award | 118,194 | $0.00 | $0.00 | filing |
| 2025-11-24 | Marotta John· President and CEO | Award | 122,269 | $0.00 | $0.00 | filing |
| 2025-11-24 | Lin Lawrence Y.· EVP, CFO and Treasurer | Award | 36,681 | $0.00 | $0.00 | filing |
| 2025-11-24 | Pirogova Olga· SVP and CHRO | Award | 16,303 | $0.00 | $0.00 | filing |
| 2025-11-24 | Starr Ephraim· SVP, Gen Counsel & Secretary | Award | 34,235 | $0.00 | $0.00 | filing |
| 2025-11-14 | Marotta John· President and CEO | Tax withholding | 10,980 | $29.75 | $326,655.00 | filing |
| 2025-11-14 | Lin Lawrence Y.· EVP, CFO and Treasurer | Tax withholding | 3,039 | $29.75 | $90,410.25 | filing |
| 2025-11-14 | Pirogova Olga· SVP and CHRO | Tax withholding | 1,553 | $29.75 | $46,201.75 | filing |
| 2025-11-14 | Zhou Ginger· SVP and GM, Multiomics | Tax withholding | 1,118 | $29.75 | $33,260.50 | filing |
| 2025-09-10 | Marotta John· President and CEO | Sale | 316 | $29.41 | $9,293.56 | filing |
| 2025-08-12 | Pirogova Olga· SVP and CHRO | Sale | 1,085 | $28.54 | $30,965.90 | filing |
| 2025-08-12 | Zhou Ginger· SVP and GM, Multiomics | Sale | 1,085 | $28.54 | $30,965.90 | filing |
| 2025-08-12 | Zhou Ginger· SVP and GM, Multiomics | D | 1,085 | $28.54 | $30,965.90 | filing |
| 2025-08-12 | Pirogova Olga· SVP and CHRO | D | 1,085 | $28.54 | $30,965.90 | filing |
| 2025-08-11 | Lin Lawrence Y.· EVP, CFO and Treasurer | Buy | 2,500 | $27.96 | $69,900.00 | filing |
Latest 24 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.